The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of ...

Coccidioidomycosis has been associated with infliximab and etanercept therapy, but not with adalimumab therapy. The case presented here is not likely to be the only case of adalimumab-induced ...

and one over 2 h (infliximab or placebo). AMPLE Study. Patients were assigned to receive 125 mg abatacept, administered sc. once per week (without an iv. loading dose), or 40 mg adalimumab ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Biologics approved by the Food and Drug Administration (FDA) for managing ulcerative colitis include: Anti-TNF agents, such ...

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...